hVIVO conduct research using the Human Challenge Model. The Human Challenge Model is a study during which healthy volunteers are deliberately exposed to a virus, known as the “challenge virus”. This is different to standard vaccine clinical trials where volunteers are exposed to viruses naturally. The Human Challenge Model can provide a more efficient and faster way to develop vaccines as fewer volunteers are required.
By registering your interest to join in the COVID-19 Human Challenge studies, your details will be stored on the Flucamp database and we will only use your contact details to provide you with information about future human challenge studies.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).